

Citations and Reference Literature: Policosanol

Citations

1. Castano G, Mas R, Fernandez L et al. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. *Int J Clin Pharmacol Res* 2001;21:43-57.
2. Mesa AR, Mas R, Noa M et al. Toxicity of policosanol in beagle dogs: one-year study. *Toxicol Lett* 1994;73:81-90.
3. Fernandez L, Mas R, Illnait J et al. Policosanol: results of a postmarketing surveillance of 27,879 patients. *Curr Ther Res* 1998;59:717-722.
4. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. *Am Heart J* 2002;143:356-365.
5. Aleman CL, Puig MN, Elias EC et al. Carcinogenicity of policosanol in mice: an 18-month study. *Food Chem Toxicol* 1995;33:573-578.
6. Aleman CL, Mas R, Hernandez C et al. A 12-month study of policosanol oral toxicity in Sprague Dawley rats. *Toxicol Lett* 1994;70:77-87.
7. Rodriguez MD, Garcia H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. *Teratog Carcinog Mutagen* 1994;14:107-113.
8. Rodriguez MD, Sanchez M, Garcia H. Multigeneration reproduction study of policosanol in rats. *Toxicol Lett* 1997;90:97-106.
9. Rodriguez MD, Garcia H. Evaluation of peri- and post-natal toxicity of policosanol in rats. *Teratog Carcinog Mutagen* 1998;18:1-7.
10. Berthold HK, Unverdorben S, Degenhardt R et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. *JAMA* 2006;295:2262-2269.
11. Dulin MF, Hatcher LF, Sasser HC, Barringer TA. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. *Am J Clin Nutr* 2006;84:1543-1548.
12. Arruzazabala ML, Valdes S, Mas R et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. *Pharmacol Res* 1996;34:181-185.
13. Valdes S, Arruzazabala ML, Fernandez L et al. Effect of policosanol on platelet aggregation in healthy volunteers. *Int J Clin Pharmacol Res* 1996;16:67-72.
14. Carbajal D, Arruzazabala ML, Valdes S, Mas R. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. *Prostaglandins Leukot Essent Fatty Acids* 1998;58:61-64.
15. Arruzazabala ML, Valdes S, Mas R et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. *Pharmacol Res* 1997;36:293-297.
16. Castano G, Mas Ferreiro R, Fernandez L et al. A long-term study of policosanol in the treatment of intermittent claudication. *Angiology* 2001;52:115-125.
17. Arruzazabala ML, Molina V, Mas R et al. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. *Clin Exp Pharmacol Physiol* 2002;29:891-897.
18. Noa M, Herrera M, Magraner J, Mas R. Effect of policosanol on isoprenaline-induced myocardial necrosis in rats. *J Pharm Pharmacol* 1994;46:282-285.
19. Carbajal D, Arruzazabala ML, Valdes S, Mas R. Interaction policosanol-warfarin on bleeding time and thrombosis in rats. *Pharmacol Res* 1998;38:89-91.
20. Molina Cuevas V, Arruzazabala ML, Carbajal Quintana D et al. Effect of policosanol on arterial blood pressure in rats. Study of the pharmacological interaction with nifedipine and propranolol. *Arch Med Res* 1998;29:21-24. Erratum in: *Arch Med Res* 1998;29:361.
21. Castano G, Mas R, Gamez R et al. Concomitant use of policosanol and beta-blockers in older patients. *Int J Clin Pharmacol Res* 2004;24:65-77.
22. Cubeddu LX, Cubeddu RJ, Heimowitz T et al. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. *Am Heart J* 2006;152:982 e981-985.
23. McCarty MF. An ezetimibe-policosanol combination has the potential to be an OTC agent that could dramatically lower LDL cholesterol without side effects. *Med Hypotheses* 2005;64:636-645.

Reference Literature

- [No authors listed.] A close look at coenzyme Q10 and policosanol: do these supplements live up to their claims for improving heart health? *Harv Heart Lett* 2002;13(4):6.
- [No authors listed.] Cholesterol-lowering action of policosanol compares well to that of pravastatin and lovastatin. *Cardiovasc J S Afr* 2003;14(3):161.
- [No authors listed.] Complementary care: how statin alternatives stack up: some help control cholesterol; others are potentially harmful. *Heart Advis* 2005;8(1):4-5.

Citations and Reference Literature: Policosanol

- [No authors listed.] Monograph. policosanol. *Altern Med Rev* 2004;9(3):312-317. (Review)
- [No authors listed.] New policosanol product combines natural cholesterol lowering with omega-3 fatty acids to lower CV risk. *Cardiovasc J S Afr* 2006;17(2):92.
- Alcocer L, Fernandez L, Campos E, et al. A comparative study of policosanol versus acipimox in patients with type II hypercholesterolemia. *Int J Tissue React* 1999;21(3):85-92.
- Aleman CL, Mas Ferreiro R, Noa Puig M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: a 24 month study. *Teratog Carcinog Mutagen* 1994;14(5):239-249.
- American Herbal Products Association. Use of marker compounds in manufacturing and labeling botanically derived dietary supplements. Silver Spring, MD: American Herbal Products Association; 2001.
- Aneiros E, Mas R, Calderon B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. *Curr Ther Res* 1995;56:176-182.
- Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. *Circulation* 2003;108:2751-2756.
- Arruzazabala ML, Carbajal D, Mas R, et al. Effects of policosanol on platelet aggregation in rats. *Thromb Res* 1993;69(3):321-327.
- Arruzazabala ML, Carbajal D, Mas R, et al. Cholesterol-lowering effects of policosanol in rabbits. *Biol Res* 1994;27(3-4):205-208.
- Arruzazabala ML, Carbajal D, Mas R, et al. Pharmacological interaction between policosanol and nitroprusside in rats. *J Med Food* 2001;4(2):67-70.
- Arruzazabala ML, Mas R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. *Int J Tissue React* 1998;20(4):119-124.
- Arruzazabala ML, Molina V, Carbajal D, et al. Effect of policosanol on cerebral ischemia in Mongolian gerbils: role of prostacyclin and thromboxane A₂. *Prostaglandins Leukot Essent Fatty Acids* 1993;49(3):695-697.
- Arruzazabala ML, Noa M, Menendez R, et al. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. *Braz J Med Biol Res* 2000;33(7):835-840.
- Batista J, Stusser R, Saez F, et al. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients: a 14-month pilot study. *Int J Clin Pharmacol Ther* 1996;34(3):134-137.
- Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. *Drug Saf* 1998;19(5):355-371. (Review)
- Bays H, Stein EA. Pharmacotherapy for dyslipidaemia: current therapies and future agents. *Expert Opin Pharmacother* 2003;4(11):1901-1938.
- Berthold HK, Unverdorben S, Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. *JAMA* 2006;295(19):2262-2269.
- Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001;345(22):1583-1592.
- Brown WV, Moussa M. Perspectives from the antihypertensive and lipid-lowering treatment to prevent heart attack trial: lipid lowering trial and the anglo-scandinavian cardiac outcomes trial: lipid lowering arm. *Curr Opin Lipidol* 2003;14(6):593-597.
- Cabrera L, Gonzalez V, Uribarri E, et al. Study of the stability of tablets containing 10 mg of policosanol as active principle. *Boll Chim Farm* 2002;141(3):223-229.
- Cabrera L, Uribarri E, Laguna A, et al. Study of the interaction between policosanol and excipients. *Boll Chim Farm* 2002;141(2):138-142.
- Canetti M, Moreiro M, Illnait J et al. One-year study of the effect of policosanol on lipid profile in patients with type II hypercholesterolemia. *Adv Ther* 1995;12:245-254.
- Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. *Int J Clin Pharmacol Res* 1995;15(4):159-165.
- Carbajal D, Arruzazabala ML, Mas R, et al. Effect of policosanol on experimental thrombosis models. *Prostaglandins Leukot Essent Fatty Acids* 1994;50(5):249-251.
- Castano G, Fernandez L, Mas R, et al. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. *Int J Clin Pharmacol Res* 2002;22(2):55-66.
- Castano G, Fernandez L, Mas R, et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. *Drugs R D* 2005;6(4):207-219.
- Castano G, Mas Ferreiro R, Fernandez L, et al. A long-term study of policosanol in the treatment of intermittent claudication. *Angiology* 2001;52(2):115-125.
- Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelium in older hypercholesterolemic patients. *Int J Clin Pharmacol Res* 1999;19(4):105-116.

Citations and Reference Literature: Policosanol

- Castano G, Mas R, Fernandez L, et al. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study. *Drugs Exp Clin Res* 2005;31(Suppl):31-44.
- Castano G, Mas R, Fernandez JC, et al. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. *Drugs R D* 2002;3(3):159-172.
- Castano G, Mas R, Fernandez JC, et al. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. *J Gerontol A Biol Sci Med Sci* 2001;56(3):M186-192.
- Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. *Gynecol Endocrinol* 2000;14(3):187-195.
- Castano G, Mas R, Fernandez L, et al. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. *Angiology* 2003;54(1):25-38.
- Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. *Drugs Aging* 2003;20(2):153-163.
- Castano G, Mas R, Roca J, et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. *Angiology* 1999;50(2):123-130.
- Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. *Int J Clin Pharmacol Res* 2002;22(3-4):89-99.
- Chen JT, Wesley R, Shamburek RD, et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. *Pharmacotherapy* 2005;25(2):171-183. (Meta-analysis)
- Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary artery disease. *N Engl J Med* 2006;354:1264-1272.
- Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. *Int J Clin Pharmacol Res* 1999;19(4):117-127.
- Cubeddu LX, Cubeddu RJ, Heimowitz T, et al. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. *Am Heart J* 2006;152(5):982.e1-e5.
- Davidson MH, Geohas CT. Efficacy of over-the-counter nutritional supplements. *Curr Atheroscler Rep* 2003;5(1):15-21. (Review)
- Dulin MF, Hatcher LF, Sasser HC, et al. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. *Am J Clin Nutr* 2006;84(6):1543-1548.
- Ehrhardt M, Lindenmaier H, Burhenne J, et al. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. *Biochem Pharmacol* 2004;67(2):285-292.
- Fernandez S, Mas R, Gamez R, et al. A pharmacological surveillance study of the tolerability of policosanol in the elderly population. *Am J Geriatr Pharmacother* 2004;2(4):219-229.
- Fontani G, Maffei D, Lodi L. Policosanol, reaction time and event-related potentials. *Neuropsychobiology* 2000;41(3):158-165.
- Fraga V, Menendez R, Amor AM, et al. Effect of policosanol on in vitro and in vivo rat liver microsomal lipid peroxidation. *Arch Med Res* 1997;28(3):355-360.
- Gamez R, Aleman CL, Mas R, et al. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague-Dawley rats. *J Med Food* 2001;4(2):57-65.
- Gamez R, Maz R, Arruzazabala ML, et al. Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits. *Drugs R D* 2005;6(1):11-19.
- Gaw A. A new reality: achieving cholesterol-lowering goals in clinical practice. *Atheroscler Suppl* 2002;2(4):5-11. (Review)
- Ghirlanda G, Oradei A, Manto A. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. *J Clin Pharmacol* 1993;33(3):226-229.
- Gonzalez Canavaciolo VL, Magraner Hernandez J. Validation of a gas chromatographic method for determining fatty alcohols that compose policosanol in five-milligram film-coated tablets. *J AOAC Int* 1999;82(4):834-839.
- Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. *Am Heart J* 2002;143(2):356-365. (Review)
- Greyling A, De Witt C, Oosthuizen W, et al. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. *Br J Nutr* 2006;95(5):968-975.
- Jacobson TA. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. *Expert Opin Drug Saf* 2003;2(3):269-286. (Review)
- Jacoby D, Mohler ER III. Drug treatment of intermittent claudication. *Drugs* 2004;64(15):1657-1670. (Review)
- Janikula M. Policosanol: a new treatment for cardiovascular disease? *Altern Med Rev* 2002;7(3):203-217. (Review)

Citations and Reference Literature: Policosanol

- Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. *Circulation* 2006;114(25):2788-2797.
- Kassis AN, Jones PJ. Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons. *Am J Clin Nutr* 2006;84(5):1003-1008.
- Kassis AN, Marinangeli CP, Jain D, et al. Lack of effect of sugar cane policosanols on plasma cholesterol in golden syrian hamsters. *Atherosclerosis* 2006. Epub ahead of print.
- Manuel-Y-Keenoy B, Van Campenhout C, Vertommen J, et al. Effects of Atorvastatin on LDL sub-fractions and peroxidation in type 1 diabetic patients: a randomised double-blind placebo-controlled study. *Diabetes Metab Res Rev* 2003;19(6):478-486.
- Marrero Delange D, Gonzalez Bravo L. Trace determination of 1-octacosanol in rat plasma by solid-phase extraction with Tenax GC and capillary gas chromatography. *J Chromatogr B Biomed Sci Appl* 2001;762(1):43-49.
- Mas R, Castano G, Illnait J, et al. Effects of policosanols in patients with type II hypercholesterolemia and additional coronary risk factors. *Clin Pharmacol Ther* 1999;65(4):439-447.
- Mas R, Menendez R, Fraga V, et al. Modification of rat lipoprotein peroxidation by oral administration of policosanols: abstract from the 4th International Conference on Preventive Cardiology: 1997 June 29-July 3. *Can J Cardiol* 13(Suppl B):310B.
- McCarty MF. Adjuvant strategies for prevention of glomerulosclerosis. *Med Hypotheses* 2006;67(6):1277-1296.
- McCarty MF. Iatrogenic lipodystrophy in HIV patients: the need for very-low-fat diets. *Med Hypotheses* 2003;61(5-6):561-566.
- McCarty MF. IGF-I activity may be a key determinant of stroke risk: a cautionary lesson for vegans. *Med Hypotheses* 2003;61(3):323-334.
- McCarty MF. Policosanol safely down-regulates HMG-CoA reductase: potential as a component of the Esselstyn regimen. *Med Hypotheses* 2002;59(3):268-279. (Review)
- McCarty MF. Toward prevention of Alzheimers disease: potential nutraceutical strategies for suppressing the production of amyloid beta peptides. *Med Hypotheses* 2006;67(4):682-697.
- McCarty MF, Block KI. Toward a core nutraceutical program for cancer management. *Integr Cancer Ther* 2006;5(2):150-171. Erratum in *Integr Cancer Ther* 2006;5(3):269. (Review)
- Menendez R, Amor AM, Gonzalez RM, et al. Effect of policosanols on the hepatic cholesterol biosynthesis of normocholesterolemic rats. *Biol Res* 1996;29(2):253-257.
- Menendez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. *Arch Med Res* 2001;32(1):8-12.
- Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanols on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. *Br J Nutr* 1997;77(6):923-932.
- Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. *Biol Res* 1994;27(3-4):199-203.
- Menendez R, Fraga V, Amor AM, et al. Oral administration of policosanols inhibits in vitro copper ion-induced rat lipoprotein peroxidation. *Physiol Behav* 1999;67(1):1-7.
- Menendez R, Marrero D, Mas R, et al. In vitro and in vivo study of octacosanol metabolism. *Arch Med Res* 2005;36(2):113-119.
- Menendez R, Mas R, Amor AM, et al. Effects of policosanols treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. *Br J Clin Pharmacol* 2000;50(3):255-262.
- Menendez R, Mas R, Amor AM, et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D003, a mixture of very long-chain saturated fatty acids. *Can J Physiol Pharmacol* 2002;80(1):13-21.
- Mirkin A, Mas R, Martinto M, et al. Efficacy and tolerability of policosanols in hypercholesterolemic postmenopausal women. *Int J Clin Pharmacol Res* 2001;21(1):31-41.
- Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. *Arzneimittelforschung* 1999;49(4):324-329.
- Molina Cuevas V, Arruzazabala ML, Carbajal Quintana D, et al. Effect of policosanols on arterial blood pressure in rats: study of the pharmacological interaction with nifedipine and propranolol. *Arch Med Res* 1998;29(1):21-24. Erratum in *Arch Med Res* 1998;29(4):361.
- Molina V, Arruzazabala ML, Carbajal D, et al. Effect of policosanols on cerebral ischemia in Mongolian gerbils. *Braz J Med Biol Res* 1999;32(10):1269-1276.
- Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. *Mol Aspects Med* 1997;18(Suppl):S137-144.
- Nies LK, Cymbala AA, Kasten SL, et al. Complementary and alternative therapies for the management of dyslipidemia. *Ann Pharmacother* 2006;40(11):1984-1992. (Review)

Citations and Reference Literature: Policosanol

- Noa M, de la Rosa MC, Mas R. Effect of policosanol on foam-cell formation in carrageenan-induced granulomas in rats. *J Pharm Pharmacol* 1996;48(3):306-309.
- Noa M, Mas R. Protective effect of policosanol on atherosclerotic plaque on aortas in monkeys. *Arch Med Res* 2005;36(5):441-447.
- Noa M, Mas R, de la Rosa MC, et al. Effect of policosanol on lipofundin-induced atherosclerotic lesions in rats. *J Pharm Pharmacol* 1995;47(4):289-291.
- Noa M, Mas R, Mendoza S, et al. Policosanol prevents bone loss in ovariectomized rats. *Drugs Exp Clin Res* 2004;30(3):117-123.
- Noa M, Mas R, Mesa R. A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery. *Pharmacol Res* 2001;43(1):31-37.
- Noa M, Mas R, Mesa R. Effect of policosanol on circulating endothelial cells in experimental models in Sprague-Dawley rats and in rabbits. *J Pharm Pharmacol* 1997;49(10):999-1002.
- Noa M, Mas R, Mesa R. Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. *Int J Cardiol* 1998;67(2):125-132.
- Noa M, Mendoza S, Mas R, et al. Effect of policosanol on carbon tetrachloride-induced acute liver damage in Sprague-Dawley rats. *Drugs R D* 2003;4(1):29-35.
- Ortega LL, Sanchez J, Mas R, et al. Effects of policosanol on patients with ischemic stroke: a pilot open study. *J Med Food* 2006;9(3):378-385.
- Ortensi G, Gladstein J, Valli H, et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. *Curr Ther Res* 1997;58:390-401.
- Pepping J. Policosanol. *Am J Health Syst Pharm* 2003;60(11):1112-1115. (Review)
- Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. *Int J Clin Pharmacol Res* 1994;14(1):27-33.
- Prat H, Roman O, Pino E. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia.] *Rev Med Chil* 1999;127(3):286-294. [Spanish]
- Re L, Barocci S, Capitani C, et al. Effects of some natural extracts on the acetylcholine release at the mouse neuromuscular junction. *Pharmacol Res* 1999;39(3):239-245.
- Rodriguez-Echenique C, Mesa R, Mas R, et al. Effects of policosanol chronically administered in male monkeys (*Macaca arctoides*). *Food Chem Toxicol* 1994;32(6):565-575.
- Setnikar I, Senin P, Rovati LC. Antiatherosclerotic efficacy of policosanol, red yeast rice extract and astaxanthin in the rabbit. *Arzneimittelforschung* 2005;55(6):312-317.
- Sierra R, Gonzalez VL, Magraner J. Validation of a gas chromatographic method for determination of fatty alcohols in 10 mg film-coated tablets of policosanol. *J AOAC Int* 2002;85(3):563-566.
- Singh DK, Li L, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. *J Pharmacol Exp Ther* 2006;318(3):1020-1026.
- Stusser R, Batista J, Padron R, et al. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients. *Int J Clin Pharmacol Ther* 1998;36(9):469-473.
- Tall AR. Protease variants, LDL, and coronary heart disease. *N Engl J Med* 2006;354:1310-1312. (Editorial)
- Tedeschi-Reiner E, Reiner Z, Romic Z, et al. [A randomized, double-blind, placebo-controlled study of the antilipemic efficacy and tolerability of food supplement policosanol in patients with moderate hypercholesterolemia.] *Lijec Vjesn* 2005;127(11-12):273-279. [Croatian]
- Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. *Diabetes Care* 1995;18(3):393-397.
- Uribarri E, Laguna A, Sierra R, et al. Physico-mechanical characterization of policosanol, a novel hypocholesterolemic drug. *Drug Dev Ind Pharm* 2002;28(1):89-93.
- Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med* 2006;355(25):2631-2639.
- Wang Y, Ebine N, Jia X, et al. Very long chain fatty acids (policosanols) and phytosterols affect plasma lipid levels and cholesterol biosynthesis in hamsters. *Metabolism* 2005;54(4):508-514.
- Wang YW, Jones PJ, Pischel I, et al. Effects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters. *Lipids* 2003;38(2):165-170.
- Ware JH. The limitations of risk factors as diagnostic tools. *N Engl J Med* 2006;355(25):2615-2617. (Editorial)
- Wei L, Murphy MJ, MacDonald TM. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. *Heart* 2006;92(6):746-751.

Citations and Reference Literature: Policosanol

Welzig CM, Shin DG, Park HJ, et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: α_2 , a possible molecular marker for parasympathetic responsiveness. *Circulation* 2003;108:2743-2746.